UNSPSC 51384612: Kebuzone or ketophenylbutazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VD83UL6Y6, chemically known as 3,5-pyrazolidinedione, 1,2-diphenyl-4-(3-oxobutyl)- but generally known as kebuzone, which bears US NIH Compound Identifier 3824. European Medicines Agency schedules Kebuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08363MIG.

UNSPSC 51384612 Kebuzone or ketophenylbutazone, a Commodity code, nominally describes a specific nonsteroidal anti-inflammatory drug used in veterinary medicine, but recent state and local procurement activity under this code does not reflect that narrow scope. The code shows little relevant activity aligned to its stated product; instead, the most recent solicitations tagged under it address broader pharmaceutical procurement, including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local issuing bodies pursuing pharmaceutical supply contracts—including county health departments, state health and human services agencies, and cooperative purchasing alliances—are using this code or related pharmaceutical classifications when procuring medication and medical supplies, though the mismatch between the code's nominal drug and the solicitations tagged beneath it suggests coding imprecision in the state and local procurement systems tagging these opportunities.

Recent activity spans three states and covers different procurement mechanisms. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside of traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Business development professionals should note that this code's recent procurement signals reflect pharmaceutical supply and distribution strategy rather than the specific ketophenylbutazone product the code nominally describes.